Johnson & Johnson Profit Slumps 89% on Charges - WSJ.com (references to Doxil/drug shortages)

"Mr. Weldon said J&J learned a "painful lesson" from the ongoing supply shortage for its drug Doxil, which treats ovarian and other cancers, and will try to have better contingency plans to avoid such disruptions in the future.
J&'s sole supplier for Doxil, Ben Venue Laboratories, late last year suspended production at its Ohio plant to focus on fixing manufacturing deficiencies cited by government regulators, including contamination. Ben Venue, a unit of Boehringer Ingelheim GmbH, doesn't expect to have new Doxil supplies until late 2012............"